



Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet	2	of	2	Attorney Docket Number	011823-004012US
-------	---	----	---	------------------------	-----------------

Complete if Known

Application Number	10/084,825
Filing Date	February 25, 2002
First Named Inventor	Co, Man Sung
Art Unit	1642
Examiner Name	Larry Helms
Attorney Docket Number	011823-004012US

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
20	AC	CO et al., "Genetically engineered deglycosylation of the variable domain increases the affinity of an anti-CD33 monoclonal antibody," <u>Mol. Immunol.</u> , 30:1361 (1993).	
20	AD	COLMA et al., "Position effects of variable region carbohydrate on the affinity and in vivo behavior of an anti- (1-6) dextran antibody," <u>Jour. Immunol.</u> , 162:2162 (1999).	
20	AE	GALA et al., "V region carbohydrate and antibody expression," <u>Jour. Immunol.</u> , 172:5494 (2004).	

Examiner Signature		Date Considered	8/2/04
-----------------------	--	--------------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.